Plasma TP53 as an indicator of poor survival in neoadjuvant-treated triple negative breast cancer: A prospective study and meta-analysis. This is an ASCO Meeting Abstract from the 2025 ASCO Annual ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback